Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Shiraz E-Medical Journal
  4. Articles

  5. Cost - effectiveness and Cost - utility of CinnoVex versus ReciGen in Patients with Relapsing - Remitting Multiple Sclerosis in Iran
  6. Scopus by Title (Ref)

Shiraz E-Medical Journal

Home
Current IssueAll IssuesIn PressAccepted ManuscriptsSearch
Instructions
Journal InformationBoards and CommitteesIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormAnnouncementSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Current Status of Studies Measuring Health State Utility for 121 Rare Diseases

- Feng J. , et al.

2. Economic burden of multiple sclerosis: a cross-sectional study in Iran

- Rezaee M. , et al.

3. How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review

- Wiyani A. , et al.

4. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C

- Goudarzi Z. , et al.

5. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran

- Zahedi Z. , et al.

HomeInstructionsAPC

Articles

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Boards and Committees
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Announcement
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.